News Releases

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two...

Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024

Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results HAMBURG, Germany, Oct. 17, 2025 /PRNewswire/ -- MVZ HPH Institute for...

Together with New Oura Ring 4 Charging Case, Multi-Ring Support, and In-App Bloodwork with Health Panels, the Ceramic Collection Gives Members More Freedom, Style, and Deeper Health Insights SAN...

Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data BOSTON, MA — [September 30, 2025] —...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025,...

With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive...

Implementation will enable users to purchase, schedule appointments for testing, and receive results of lab tests performed by Quest within the WHOOP app, supporting access to deeper health and...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the...

New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics...

Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the...

Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of...

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology...

Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5%...

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J., July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J.,...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report. The theme of the report, Care Starts Here, reflects the...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed...

Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21,...

More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite...

First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity...

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the...

Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and...

Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday,...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune®...

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7%...

Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND, Jan. 27, 2025 /PRNewswire/ -- Quest...

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30,...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ --...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January...

Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month...

Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from...

The Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) applauds the National Comprehensive Cancer Network (NCCN) for recent updates to its Genetic/Familial High-Risk...

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and...

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the...

Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at...

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics...

Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount...

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October...

One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J., Aug....

Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J., Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a...

Second quarter revenues of $2.40 billion, up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2%...

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage...

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. and COLUMBUS, Ohio, July 10, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's...

Transaction to broaden access to Quest's innovative and cost-effective services for providers and patients in Minnesota and western Wisconsin SECAUCUS, N.J. and MINNEAPOLIS, June 26, 2024...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024, before the...

PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer...

The Quest Diagnostics Foundation continues support of the American Heart Association’s Scholars programs with renewed investment to increase diversity in health care workforce and expand...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22,...

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been...

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce...

Foundation grant will help NYC-based nonprofit expand reach of its innovative curriculum to 50 schools in Baltimore and Houston Funding will also support film screening tour of award-winning...

First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with...

Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health...

Leading commercial organizations and patient advocacy groups in the field of cancer genetics today announced the founding of the Inter-Organization Cancer Genetics Clinical Evidence Coalition...

Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest...

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's...

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health...

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to...

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations...

Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6%...

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life...

UnderwriteMe, a leading provider of risk automation and marketplace solutions, is pleased to announce a collaboration with ExamOne, a Quest Diagnostics company, to offer life insurance carriers across

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on...

Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024...

Moleculera Labs, Inc, a precision medicine company pioneering immune-mediated neuropsychiatric testing, today announced a strategic collaboration with Quest Diagnostics (DGX: NYSE), the nation’s...

Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes FREMONT, Calif...